Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
ABEO
ABEO
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ABEO News
Abeona Launches First Gene Therapy ZEVASKYN for RDEB
1d ago
Newsfilter
Netflix Highlights a Rare Disease While Pearl Jam's Lead Singer Raises Funds for a Cure.
Feb 14 2026
Barron's
Abeona Therapeutics Grants Equity Awards to New Employees
Feb 09 2026
Newsfilter
Analysis of High Insider Ownership Growth Companies in the U.S.
Jan 01 2026
Yahoo Finance
Abeona Grants 79,584 Restricted Stock Awards to New Employees
Dec 31 2025
Globenewswire
Abeona Grants 79,584 Restricted Stock Awards to New Employees
Dec 31 2025
Newsfilter
Epidermolysis Bullosa Market Analysis 2025-2035: Innovations by Abeona, Castle Creek, RHEACELL, and Chiesi Drive Growth in Gene Therapies and Advanced Wound Care
Nov 18 2025
Yahoo Finance
Abeona Therapeutics® Announces Financial Results and Corporate Updates for Q3 2025
Nov 12 2025
Newsfilter
KalVista, Health Catalyst, and Bio-Techne Experience After-Hours Increases Following Earnings Reports
Nov 11 2025
NASDAQ.COM
Abeona Therapeutics® Sets Date for Third Quarter Financial Results and Upcoming Investor Conference Engagement
Nov 07 2025
Newsfilter
Abeona Therapeutics® Unveils New Employee Inducement Grants in Compliance with Nasdaq Listing Rule 5635(c)(4)
Nov 03 2025
Newsfilter
Abeona Therapeutics® Reveals Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)
Oct 30 2025
Newsfilter
Abeona Therapeutics® Names James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President and Leader of Clinical Development & Medical Affairs
Oct 20 2025
Newsfilter
Abeona Therapeutics® Unveils ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Chosen by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Initiative
Oct 13 2025
Newsfilter
Abeona Therapeutics® Unveils New Employee Inducement Grants in Compliance with Nasdaq Listing Rule 5635(c)(4)
Oct 01 2025
Newsfilter
Oppenheimer Maintains Outperform on Abeona Therapeutics, Raises Price Target to $20
Aug 15 2025
Benzinga
Show More News
